MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories (NASDAQ:MLAB) announced on Oct 3, 2025 that its Board declared a regular quarterly dividend of $0.16 per share. The dividend is payable on Dec 15, 2025 to shareholders of record at the close of business on Nov 28, 2025.
The release includes a standard forward-looking statements caution and directs investors to the company’s Form 10-K for risks and additional information.
Mesa Laboratories (NASDAQ:MLAB) ha annunciato il 3 ottobre 2025 che il suo Consiglio ha approvato un dividendo trimestrale regolare di $0,16 per azione. Il dividendo sarà pagato il 15 dicembre 2025 agli azionisti registrati entro la chiusura delle attività del 28 novembre 2025.
Il comunicato include una cautela standard sulle dichiarazioni prospettiche e invita gli investitori a consultare il modulo 10-K della società per i rischi e ulteriori informazioni.
Mesa Laboratories (NASDAQ:MLAB) anunció el 3 de octubre de 2025 que su Junta declaró un dividendo trimestral regular de $0,16 por acción. El dividendo será pagadero el 15 de diciembre de 2025 a los accionistas registrados al cierre de operaciones del 28 de noviembre de 2025.
El comunicado incluye una advertencia estándar sobre declaraciones prospectivas y dirige a los inversionistas al Formulario 10-K de la empresa para riesgos e información adicional.
Mesa Laboratories (NASDAQ:MLAB)는 2025년 10월 3일에 이사회가 분기별 정기 배당금 $0.16/주를 선언했다고 발표했습니다. 배당금은 2025년 12월 15일에 지급되며, 2025년 11월 28일 영업 마감 시점에 등록된 주주에게 지급됩니다.
발표에는 일반적인 미래지향적 진술에 대한 주의가 포함되어 있으며, 투자자들에게 위험 및 추가 정보를 위해 회사의 10-K 양식을 참조하라고 안내합니다.
Mesa Laboratories (NASDAQ:MLAB) a annoncé le 3 octobre 2025 que son conseil d'administration a déclaré un dividende trimestriel régulier de $0,16 par action. Le dividende sera versé le 15 décembre 2025 aux actionnaires inscrits à la clôture des activités le 28 novembre 2025.
Le communiqué comprend une mise en garde standard sur les déclarations prospectives et invite les investisseurs à consulter le formulaire 10-K de l'entreprise pour les risques et des informations complémentaires.
Mesa Laboratories (NASDAQ:MLAB) gab am 3. Oktober 2025 bekannt, dass der Aufsichtsrat eine regelmäßige vierteljährliche Dividende in Höhe von $0,16 je Aktie beschlossen hat. Die Dividende wird am 15. Dezember 2025 an die am Ende des Geschäftstages des 28. November 2025 verzeichneten Aktionäre zahlbar sein.
Die Veröffentlichung enthält eine Standardwarnung zu zukunftsgerichteten Aussagen und verweist Investoren auf das Form 10-K des Unternehmens für Risiken und weitere Informationen.
Mesa Laboratories (NASDAQ:MLAB) أعلنت مجلس إدارتها في 3 أكتوبر 2025 أنه قرر توزيع أرباح ربع سنوية منتظمة قدرها $0.16 للسهم. ستكون الأرباح مستحقة الدفع في 15 ديسمبر 2025 للمساهمين المسجلين حتى إغلاق العمل في 28 نوفمبر 2025.
يتضمن البيان تحذيرًا قياسيًا من التصريحات المستقبلية ويوجه المستثمرين إلى نموذج 10-K الخاص بالشركة من أجل المخاطر ومعلومات إضافية.
Mesa Laboratories (NASDAQ:MLAB) 宣布其董事会于2025年10月3日通过常规季度股息为$0.16/股的决定。股息将于2025年12月15日支付,股权登记日为2025年11月28日收盘时在册的股东。
公告含有关于前瞻性声明的标准性警告,并指引投资者查阅公司 Form 10-K,以了解风险及其他信息。
- Declared quarterly dividend of $0.16 per share
- Dividend payable on Dec 15, 2025
- Record date set for Nov 28, 2025
- None.
Lakewood, Colo., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2025, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
CONTACT: Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website at www.mesalabs.com
